The estimated Net Worth of Xiangmin Cui is at least $113 Milion dollars as of 9 November 2023. Mr. Cui owns over 375,000 units of Alpine Immune Sciences Inc stock worth over $112,758,294 and over the last 14 years he sold ALPN stock worth over $0. In addition, he makes $0 as Independent Director at Alpine Immune Sciences Inc.
Xiangmin has made over 2 trades of the Alpine Immune Sciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 375,000 units of ALPN stock worth $4,687,500 on 9 November 2023.
The largest trade he's ever made was buying 1,542,553 units of Alpine Immune Sciences Inc stock on 17 September 2021 worth over $14,499,998. On average, Xiangmin trades about 127,837 units every 52 days since 2010. As of 9 November 2023 he still owns at least 1,735,544 units of Alpine Immune Sciences Inc stock.
You can see the complete history of Mr. Cui stock trades at the bottom of the page.
Xiangmin Cui Ph.D. serves as Independent Director of the Company. Dr. Cui has served as managing director of Decheng Capital, an investment firm focused on life sciences companies, since he founded the firm in 2011. Prior to founding Decheng, Dr. Cui was an investment partner at Bay City Capital, an international life science venture capital firm in San Francisco. Dr. Cui was previously director of strategic investment for the Southern Research Institute, a not-for-profit research organization. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui has served as a member of the board of directors of ARMO BioSciences, Inc., a publicly-traded immuno-oncology company acquired by Eli Lilly and Company in May 2018, from August 2017 to May 2018, and also currently serves on the boards of directors of several private companies. Dr. Cui holds a Ph.D. in Cancer Biology from Stanford University and a B.S and M.S in Molecular Biology from Peking University.
Xiangmin Cui is 51, he's been the Independent Director of Alpine Immune Sciences Inc since 2019. There are 8 older and 7 younger executives at Alpine Immune Sciences Inc. The oldest executive at Alpine Immune Sciences Inc is Dr. Jan L. Hillson Ph.D., M.D., 67, who is the Sr. VP of Clinical Devel..
Xiangmin's mailing address filed with the SEC is C/O ALPINE IMMUNE SCIENCES, INC., 201 ELLIOT AVENUE WEST, SUITE 230, SEATTLE, WA, 98119.
Over the last 7 years, insiders at Alpine Immune Sciences Inc have traded over $91,012,519 worth of Alpine Immune Sciences Inc stock and bought 8,061,426 units worth $69,477,679 . The most active insiders traders include Peter A. Thompson, Advisors Llc Orbi Med Capit... oraz James N Topper. On average, Alpine Immune Sciences Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,201,670. The most recent stock trade was executed by Stanford L Peng on 8 May 2024, trading 271,792 units of ALPN stock currently worth $668,608.
founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.
Alpine Immune Sciences Inc executives and other stock owners filed with the SEC include: